Audentes Therapeutics is now Astellas Gene Therapies. Read our Press Release and visit www.astellas.com to learn more.

Top Menu Team
Top Menu Our Approach
Top MenuInnovative Therapies
Top Menu Careers
Top Menu News
Top Menu Contact
Top Menu Patients + Families

Home
News

News

Feb 22, 2023

Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease

Jan 20, 2023

Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease

Jan 09, 2023

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease

Oct 25, 2022

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs

Jul 26, 2022

Astellas Unveils Plans to Open New Biotech Campus in South San Francisco

Jun 27, 2022

Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease

Jun 08, 2022

Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina

Apr 22, 2022

Notice Regarding Impairment Loss for Products under Development

Feb 07, 2022

Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Footer Menu 1

TEAM
OUR APPROACH

Footer Menu 2

INNOVATIVE THERAPIES

Footer Menu 3

CAREERS
NEWS
CONTACT
PATIENTS + FAMILIES
US PRIVACY POLICY
EU PRIVACY POLICY

225 Gateway Blvd., South
San Francisco, CA 94080
Phone: (415) 818-1005
Email: [email protected]

© Copyright 2023 Audentes Therapeutics. Terms and Conditions | Privacy Statement

Update cookie preferences

back to top